近日,美国食品药品管理局(FDA)宣布,已批准戈利木单抗(golimumab)输液剂联合甲氨蝶呤用于治疗中至重度活动性类风湿性关节炎(RA)成人患者。该批准令为这一RA药物增加了新的适应证。最初,FDA于2009年批准每月1次皮下注射戈利木单抗用于治疗中至重度活动性RA、活动性银屑病关节炎和活动性强直性脊柱炎,以商品名Simponi上市。此次批准的 Recently, the U.S. Food and Drug Administration (FDA) announced that golimumab infusion and methotrexate have been approved for the treatment of adults with moderate to severe active rheumatoid arthritis (RA). The approval adds a new indication for this RA drug. Initially, the FDA approved the monthly subcutaneous injection of golimumab in 2009 for the treatment of moderate-to-severe activity RA, active psoriatic arthritis and active ankylosing spondylitis under the Simponi trade name. This time approved